Ashwagandha Should NOT Be Used in Patients with CAD and Palpitations
I strongly recommend against using ashwagandha in patients with coronary artery disease (CAD) who experience palpitations due to documented risks of thyrotoxicosis-induced arrhythmias and lack of evidence supporting its safety in this population.
Critical Safety Concerns
Documented Arrhythmogenic Risk
Ashwagandha has been directly linked to supraventricular tachycardia through thyrotoxicosis 1. A case report documented a 73-year-old woman who developed supraventricular tachycardia and hyperthyroidism with significantly suppressed TSH after two years of ashwagandha use. The arrhythmia and thyroid dysfunction resolved completely upon discontinuation 1.
This is particularly dangerous in CAD patients because:
- Tachyarrhythmias increase myocardial oxygen demand
- Patients with CAD have limited coronary reserve
- Palpitations may represent underlying ventricular arrhythmias requiring evaluation 2
Endocrine Disruption
A comprehensive 2026 review identified thyrotoxicosis and adrenal suppression as significant adverse effects of ashwagandha, particularly with prolonged use 3. The endocrine-modulating activity can trigger:
- Thyroid hormone excess → increased heart rate and arrhythmias
- Metabolic stress that exacerbates cardiac ischemia
- Unpredictable interactions with cardiovascular medications
Hepatotoxicity Risk
Ashwagandha undergoes metabolic transformation via cytochrome P450 enzymes, forming reactive intermediates that cause oxidative stress and hepatotoxicity 3. This creates potential drug interactions with:
- Beta-blockers (recommended for CAD patients) 4, 5
- Statins (essential for CAD management)
- Antiplatelet agents
What CAD Patients with Palpitations Actually Need
Immediate Evaluation Required
Palpitations in CAD patients demand proper workup, not herbal supplements 2:
- 12-lead ECG during symptoms (Class I recommendation) 2
- Ambulatory ECG monitoring to detect and diagnose arrhythmias 2
- Echocardiography to assess LV function and structural disease 2
- Exercise testing if ischemia suspected 2
Evidence-Based Medical Management
For CAD patients, the proven approach includes 4, 5, 6:
For Symptom Control:
- Beta-blockers as first-line (Class I) - reduce heart rate, control palpitations, prevent ischemia 4, 5
- Calcium channel blockers if beta-blockers contraindicated 4
- Long-acting nitrates for angina 4
For Event Prevention:
- Aspirin 75-100 mg daily (Class I) 6
- Statins for lipid management 5
- ACE inhibitors or ARBs especially with hypertension, diabetes, or LV dysfunction 4, 5
Blood Pressure Targets
Target BP 120-130/80 mmHg (130-140 systolic if >65 years) 5. Avoid diastolic BP <60 mmHg as this can worsen myocardial ischemia 4.
Common Pitfalls to Avoid
Do not dismiss palpitations as benign - In CAD patients, they may represent ventricular arrhythmias requiring electrophysiological study 2
Do not rely on symptom relief as diagnostic - Even GI cocktails can relieve chest discomfort in 41% of patients without CAD 7, 8
Do not use unproven supplements instead of guideline-directed therapy - While one small pilot study showed ayurvedic therapy improved arterial function 9, this was a comprehensive program, not ashwagandha alone, and lacks the robust evidence base of standard CAD therapies
Do not ignore drug interactions - Ashwagandha's P450 metabolism creates unpredictable interactions with essential cardiac medications 3
The Bottom Line
While ashwagandha may have stress-reduction properties in healthy individuals 10, 11, there is zero evidence supporting its use in CAD patients with palpitations. The documented risk of thyrotoxicosis-induced arrhythmias 1, potential for hepatotoxicity 3, and lack of cardiovascular outcome data make it inappropriate for this population.
Patients with CAD and palpitations require proper arrhythmia evaluation and evidence-based medical therapy with beta-blockers, antiplatelet agents, and statins - not herbal supplements with documented cardiac risks.